Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY 30.04
(-0.07%)
CNY 30.04
(-0.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.39 Billion CNY | 31.13% |
| 2022 | 1.82 Billion CNY | 27.8% |
| 2021 | 1.42 Billion CNY | 272.38% |
| 2020 | 383.06 Million CNY | 18.18% |
| 2019 | 324.12 Million CNY | -1.79% |
| 2018 | 330.04 Million CNY | 6.16% |
| 2017 | 310.9 Million CNY | 168.46% |
| 2016 | 115.81 Million CNY | -7.06% |
| 2015 | 124.61 Million CNY | 43.91% |
| 2014 | 86.59 Million CNY | 6.11% |
| 2013 | 81.6 Million CNY | 60.83% |
| 2012 | 50.73 Million CNY | 65.41% |
| 2011 | 30.67 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.62 Billion CNY | 9.6% |
| 2024 Q3 | 2.29 Billion CNY | 1.22% |
| 2024 Q2 | 2.27 Billion CNY | -13.27% |
| 2023 Q4 | 2.39 Billion CNY | 0.71% |
| 2023 FY | 2.39 Billion CNY | 31.13% |
| 2023 Q3 | 2.37 Billion CNY | -0.49% |
| 2023 Q2 | 2.38 Billion CNY | 9.41% |
| 2023 Q1 | 2.17 Billion CNY | 19.58% |
| 2022 Q2 | 1.43 Billion CNY | 4.1% |
| 2022 Q1 | 1.37 Billion CNY | -3.47% |
| 2022 FY | 1.82 Billion CNY | 27.8% |
| 2022 Q4 | 1.82 Billion CNY | 18.89% |
| 2022 Q3 | 1.53 Billion CNY | 6.96% |
| 2021 Q2 | 1.26 Billion CNY | 224.69% |
| 2021 FY | 1.42 Billion CNY | 272.38% |
| 2021 Q1 | 389.42 Million CNY | 1.66% |
| 2021 Q3 | 1.26 Billion CNY | -0.11% |
| 2021 Q4 | 1.42 Billion CNY | 12.94% |
| 2020 Q2 | 338 Million CNY | -4.32% |
| 2020 FY | 383.06 Million CNY | 18.18% |
| 2020 Q1 | 353.26 Million CNY | 8.99% |
| 2020 Q4 | 383.06 Million CNY | 32.81% |
| 2020 Q3 | 288.43 Million CNY | -14.66% |
| 2019 Q1 | 326.33 Million CNY | -1.12% |
| 2019 Q2 | 315.57 Million CNY | -3.3% |
| 2019 Q3 | 312.44 Million CNY | -0.99% |
| 2019 Q4 | 324.12 Million CNY | 3.74% |
| 2019 FY | 324.12 Million CNY | -1.79% |
| 2018 FY | 330.04 Million CNY | 6.16% |
| 2018 Q4 | 330.04 Million CNY | 16.73% |
| 2018 Q3 | 282.73 Million CNY | 7.63% |
| 2018 Q2 | 262.69 Million CNY | -17.46% |
| 2018 Q1 | 318.24 Million CNY | 2.36% |
| 2017 Q1 | 250.11 Million CNY | 115.97% |
| 2017 FY | 310.9 Million CNY | 168.46% |
| 2017 Q4 | 310.9 Million CNY | 16.24% |
| 2017 Q3 | 267.46 Million CNY | 0.0% |
| 2017 Q2 | 267.46 Million CNY | 6.94% |
| 2016 FY | 115.81 Million CNY | -7.06% |
| 2016 Q3 | 97.44 Million CNY | -12.03% |
| 2016 Q2 | 110.76 Million CNY | -1.55% |
| 2016 Q1 | 112.51 Million CNY | -9.71% |
| 2016 Q4 | 115.81 Million CNY | 18.85% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | 124.61 Million CNY | 43.91% |
| 2015 Q4 | 124.61 Million CNY | 0.0% |
| 2015 Q2 | 96.61 Million CNY | 0.0% |
| 2014 FY | 86.59 Million CNY | 6.11% |
| 2013 FY | 81.6 Million CNY | 60.83% |
| 2012 FY | 50.73 Million CNY | 65.41% |
| 2011 FY | 30.67 Million CNY | 0.0% |